|drug2939||Placebo EC-18 Wiki||0.71|
There are 2 clinical trials
Prevention of COVID-19 infection to severe pneumonea or ARDS
A trial of EC-18 in patients with mild/moderate pneumonia due to COVID-19
Description: Endotracheal intubation and mechanical ventilation Oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates > 20L/min with a fraction of delivered oxygen ≥ 0.5) Non-invasive positive pressure ventilation Extracorporeal membrane oxygenationMeasure: Respiratory failure defined based on resource utilization requiring at least 1 of the following: Time: 28 days
Description: o Check for changes in symptoms on a daily basis for 28 days compared to the baseline at day 1Measure: Confirmation of changes in subject's subjective clinical symptoms (e.g., patient questionnaire) Time: 28 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports